| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2014-12-24 |
股东大会：
将于2015-01-27召开股东大会
会议内容 ▼▲
- 1.A proposal to adopt the Amended and Restated Agreement and Plan of Merger, dated as of November 17, 2014 (the “merger agreement”), among Auxilium, Endo International plc, Endo U.S. Inc. and Avalon Merger Sub Inc. (“Merger Sub”) and approve the transactions contemplated thereby. Pursuant to the merger agreement, Merger Sub will be merged with and into Auxilium and Auxilium will continue as the surviving corporation and as a wholly owned indirect subsidiary of Endo (the “merger”);
2.A proposal to approve, on a non-binding advisory basis, certain compensatory arrangements between Auxilium and its named executive officers relating to the merger;
3.A proposal to adjourn the special meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the special meeting to adopt the merger agreement and approve the transactions contemplated thereby (the “special meeting adjournment proposal”).
|
| 2014-10-30 |
详情>>
股本变动：
变动后总股本5102.15万股
|
| 2014-10-30 |
详情>>
业绩披露：
2014年三季报(累计)每股收益-2.49美元,归母净利润-1.25亿美元,同比去年增长-724.42%
|
| 2014-09-17 |
复牌提示：
2014-09-16 16:45:02 停牌，复牌日期 2014-09-16 17:15:00
|
| 2014-08-07 |
详情>>
业绩披露：
2014年中报每股收益-1.85美元,归母净利润-9247.2万美元,同比去年增长-289%
|
| 2014-05-05 |
详情>>
业绩披露：
2014年一季报每股收益-1.12美元,归母净利润-5597.7万美元,同比去年增长-585.99%
|
| 2014-04-10 |
股东大会：
将于2014-05-21召开股东大会
会议内容 ▼▲
- 1. To elect seven directors to serve as the Company's Board of Directors (the "Board") until the Company's 2015 Annual Meeting of Stockholders or until their respective successors shall have been duly elected and qualified;
2. To ratify the selection by the Audit and Compliance Committee of the Board of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2014;
3. To approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the compensation discussion and analysis, the compensation tables and any related materials disclosed in the Proxy Statement for the Meeting;
4. To approve the amendment and restatement of the Company's Certificate of Incorporation to increase the authorized common stock capital of the Company from 120,000,000 to 150,000,000 shares;
5. To approve the amendment and restatement of the Auxilium Pharmaceuticals, Inc. 2004 Equity Compensation Plan (the "Equity Compensation Plan" or the "Plan") to increase the number of shares of Company common stock authorized for issuance under the Plan by 2,500,000 shares from 15,800,000 to 18,300,000 shares and to increase the fungible share counting ratio from 1.7 shares to 1.88 shares;
6. To transact such other business as may properly come before the Meeting or any adjournments or postponements thereof.
|
| 2014-02-28 |
详情>>
业绩披露：
2013年年报每股收益-0.37美元,归母净利润-1806.5万美元,同比去年增长-121.02%
|
| 2014-02-28 |
详情>>
业绩披露：
2011年年报每股收益-0.69美元,归母净利润-3291.6万美元,同比去年增长35.75%
|
| 2013-11-06 |
详情>>
业绩披露：
2013年三季报(累计)每股收益0.41美元,归母净利润2003.80万美元,同比去年增长544.10%
|
| 2013-08-01 |
详情>>
业绩披露：
2013年中报每股收益0.99美元,归母净利润4892.80万美元,同比去年增长718.74%
|
| 2013-04-30 |
详情>>
业绩披露：
2013年一季报每股收益-0.17美元,归母净利润-816万美元,同比去年增长-366.82%
|
| 2013-03-21 |
股东大会：
将于2013-05-01召开股东大会
会议内容 ▼▲
- 1. To elect seven directors to serve as the Company's Board of Directors (the "Board") until the Company's 2014 Annual Meeting of Stockholders or until their respective successors shall have been duly elected and qualified;
2. To ratify the selection by the Audit and Compliance Committee of the Board of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2013;
3. To approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the compensation discussion and analysis, the compensation tables and any related materials disclosed in the Proxy Statement for the Meeting;
4. To transact such other business as may properly come before the Meeting or any adjournments or postponements thereof.
|
| 2013-02-26 |
详情>>
业绩披露：
2012年年报每股收益1.76美元,归母净利润8594.40万美元,同比去年增长361.10%
|
| 2012-11-08 |
详情>>
业绩披露：
2012年三季报(累计)每股收益-0.09美元,归母净利润-451.2万美元,同比去年增长78.57%
|